- Home
- TIL vs IGA Comparison
TIL vs IGA Comparison
Compare TIL & IGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- IGA
- Stock Information
- Founded
- TIL 2018
- IGA 2005
- Country
- TIL United States
- IGA United States
- Employees
- TIL N/A
- IGA N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- IGA Investment Managers
- Sector
- TIL Health Care
- IGA Finance
- Exchange
- TIL Nasdaq
- IGA Nasdaq
- Market Cap
- TIL 177.1M
- IGA 148.2M
- IPO Year
- TIL 2021
- IGA N/A
- Fundamental
- Price
- TIL $27.84
- IGA $9.86
- Analyst Decision
- TIL Buy
- IGA
- Analyst Count
- TIL 6
- IGA 0
- Target Price
- TIL $120.50
- IGA N/A
- AVG Volume (30 Days)
- TIL 159.0K
- IGA 42.3K
- Earning Date
- TIL 08-13-2025
- IGA 01-01-0001
- Dividend Yield
- TIL N/A
- IGA 8.93%
- EPS Growth
- TIL N/A
- IGA N/A
- EPS
- TIL N/A
- IGA N/A
- Revenue
- TIL N/A
- IGA N/A
- Revenue This Year
- TIL N/A
- IGA N/A
- Revenue Next Year
- TIL N/A
- IGA N/A
- P/E Ratio
- TIL N/A
- IGA N/A
- Revenue Growth
- TIL N/A
- IGA N/A
- 52 Week Low
- TIL $9.90
- IGA $7.77
- 52 Week High
- TIL $92.00
- IGA $8.88
- Technical
- Relative Strength Index (RSI)
- TIL 52.43
- IGA 59.98
- Support Level
- TIL $25.79
- IGA $9.78
- Resistance Level
- TIL $29.67
- IGA $9.74
- Average True Range (ATR)
- TIL 2.62
- IGA 0.10
- MACD
- TIL 0.10
- IGA 0.03
- Stochastic Oscillator
- TIL 70.92
- IGA 87.60
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.